Mode and site of action of therapies targeting CGRP signaling

Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments current...

Descripción completa

Detalles Bibliográficos
Autores: Labastida Ramírez, Alejandro|||0000-0003-2079-1156, Caronna, Edoardo|||0000-0001-5525-0267, Gollion, Cédric|||0000-0001-6098-2569, Stanyer, Emily, Dapkute, Austeja|||0000-0001-7508-0971, Braniste, Diana, Naghshineh, Hoda|||0000-0002-8141-076X, Meksa, Liga, Chkhitunidze, Nino, Gudadze, Tamari, Pozo-Rosich, Patricia|||0000-0003-0796-4702, Burstein, Rami, Hoffmann, Jan|||0000-0002-2103-9081
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:319993
Acceso en línea:https://ddd.uab.cat/record/319993
https://dx.doi.org/urn:doi:10.1186/s10194-023-01644-8
Access Level:acceso abierto
Palabra clave:Amylin
Anti-CGRP
Calcitonin
Headache
Migraine
Trigeminal
Descripción
Sumario:Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed.

Similares en LA Referencia